Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94986 | 0.87 | ALDH1A1 (0.85) | ALDH1A1KMT2APOLBHPGDCYP1A2 | |
| SCHEMBL7253512 | 0.81 | ALDH1A1 (0.85) | ALDH1A1KMT2APOLBHPGDCYP1A2 | |
| SCHEMBL7252897 | 0.80 | HPGD (0.83) | ALDH1A1KMT2AHPGDCYP1A2CYP2C9 | |
| SCHEMBL5621143 | 0.78 | ALDH1A1 (1.00) | ALDH1A1KMT2APOLBHPGDCYP1A2 | |
| SCHEMBL15151528 | 0.75 | KMT2A (0.48) | ALDH1A1KMT2APOLBHPGDCYP1A2 | |
| SCHEMBL7252775 | 0.74 | KMT2A (0.66) | ALDH1A1KMT2APOLBHPGDRAB9A | |
| SCHEMBL15151529 | 0.74 | ALDH1A1 (0.49) | ALDH1A1KMT2APOLBHPGDCYP1A2 | |
| SCHEMBL16256716 | 0.74 | HPGD (0.49) | ALDH1A1KMT2APOLBHPGDCYP1A2 | |
| SCHEMBL7258078 | 0.73 | HPGD (0.83) | ALDH1A1HPGDRAB9ANPC1TSHR | |
| SCHEMBL4464908 | 0.73 | ALDH1A1 (0.82) | ALDH1A1KMT2APOLBHPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20110262525-A1 | METHODS OF TREATMENT | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262525-A1 | METHODS OF TREATMENT | ASAH2, FOLH1, CD44 | ALDH1A1 1200/4885KMT2A 2834/4885POLB 966/4885 |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | BRCA1, VHL, TP53 | ALDH1A1 484/4885KMT2A 2332/4885POLB 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.